Ultragenyx Market Cap ($1.41 Billion)
Market Cap & Net Worth: Ultragenyx (RARE)
Ultragenyx market cap. Ultragenyx (NASDAQ:RARE) has a market capitalization of $1.41 Billion ($1.41 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7186 globally and #2226 in its home market, demonstrating a 0.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ultragenyx's stock price $16.10 by its total outstanding shares 98588873 (98.59 Million). Also see Ultragenyx (RARE) cash flow conversion for how efficiently the company converts equity into cash flow.
Ultragenyx Market Cap History (2015–2026)
Ultragenyx market cap history from 2015 to 2026. Data shows change from $11.06 Billion to $1.59 Billion (-14.34% CAGR). Check RARE stock price for real-time trading data and today's change.
Index Memberships
Ultragenyx is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.12% | #20 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.05% | #211 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #810 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.08% | #124 of 263 |
Weight: Ultragenyx's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ultragenyx Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ultragenyx's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RARE net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.37x
Ultragenyx's market cap is 3.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.93 Billion | $133.00K | -$245.87 Million | 52118.67x | N/A |
| 2017 | $4.57 Billion | $2.61 Million | -$302.14 Million | 1750.59x | N/A |
| 2018 | $4.29 Billion | $51.49 Million | -$197.61 Million | 83.24x | N/A |
| 2019 | $4.21 Billion | $103.71 Million | -$402.73 Million | 40.60x | N/A |
| 2020 | $13.65 Billion | $271.03 Million | -$186.57 Million | 50.35x | N/A |
| 2021 | $8.29 Billion | $351.41 Million | -$454.02 Million | 23.59x | N/A |
| 2022 | $4.57 Billion | $363.33 Million | -$707.42 Million | 12.57x | N/A |
| 2023 | $4.71 Billion | $434.25 Million | -$606.64 Million | 10.86x | N/A |
| 2024 | $4.15 Billion | $560.23 Million | -$569.18 Million | 7.40x | N/A |
| 2025 | $2.27 Billion | $673.00 Million | -$575.00 Million | 3.37x | N/A |
Competitor Companies of RARE by Market Capitalization
Companies near Ultragenyx in the global market cap rankings as of November 1, 2026. Also see Ultragenyx (RARE) total assets for a full breakdown of the balance sheet.
Key companies related to Ultragenyx by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ultragenyx (2015–2026)
Market capitalization of Ultragenyx from 2015 to today. Between 2015 and today, Ultragenyx's market cap moved from $11.06 Billion to $ 1.59 Billion, with a yearly change of -14.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.59 Billion | -30.00% |
| 2025 | $2.27 Billion | -45.33% |
| 2024 | $4.15 Billion | -12.02% |
| 2023 | $4.71 Billion | +3.22% |
| 2022 | $4.57 Billion | -44.90% |
| 2021 | $8.29 Billion | -39.25% |
| 2020 | $13.65 Billion | +224.12% |
| 2019 | $4.21 Billion | -1.77% |
| 2018 | $4.29 Billion | -6.25% |
| 2017 | $4.57 Billion | -34.03% |
| 2016 | $6.93 Billion | -37.32% |
| 2015 | $11.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ultragenyx was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.41 Billion USD |
| MoneyControl | $1.41 Billion USD |
| MarketWatch | $1.41 Billion USD |
| marketcap.company | $1.41 Billion USD |
| Reuters | $1.41 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more